Gilead Sciences, Inc. (NASDAQ:GILD) Stake Trimmed by Bogart Wealth LLC

Bogart Wealth LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 90,565 shares of the biopharmaceutical company’s stock after selling 2,218 shares during the period. Bogart Wealth LLC’s holdings in Gilead Sciences were worth $8,366,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. AMF Tjanstepension AB grew its position in Gilead Sciences by 14.7% during the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock worth $33,645,000 after purchasing an additional 51,390 shares in the last quarter. Creative Planning lifted its holdings in shares of Gilead Sciences by 16.1% in the third quarter. Creative Planning now owns 219,045 shares of the biopharmaceutical company’s stock valued at $18,365,000 after purchasing an additional 30,451 shares in the last quarter. Swedbank AB boosted its position in shares of Gilead Sciences by 10.2% in the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after buying an additional 189,622 shares during the period. Asset Dedication LLC grew its holdings in shares of Gilead Sciences by 7.5% during the third quarter. Asset Dedication LLC now owns 4,481 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 314 shares in the last quarter. Finally, Sumitomo Life Insurance Co. raised its position in Gilead Sciences by 0.7% during the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 117 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 2.6 %

Shares of Gilead Sciences stock opened at $105.96 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company’s fifty day simple moving average is $93.38 and its 200-day simple moving average is $87.24. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $106.43. The company has a market cap of $132.05 billion, a price-to-earnings ratio of 1,177.33, a PEG ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Analyst Ratings Changes

Several research firms have weighed in on GILD. Wolfe Research assumed coverage on Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Bank of America reiterated a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $101.33.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of the business’s stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the transaction, the chief financial officer now directly owns 171,223 shares in the company, valued at $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock worth $67,684,956 in the last 90 days. 0.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.